Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative

Clinical trial NCT04842617 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04842617
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Start date: 2021-04-30
Primary completion: 2026-10-31
Enrollment: 5274

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.